Perrigo
This article was originally published in The Rose Sheet
Executive Summary
Private label manufacturer expects FDA tentative approval of its abbreviated new drug application for 5% minoxidil topical solution "well before" the three-year marketing exclusivity for Pharmacia & Upjohn expires Nov. 14, 2000. Alpharma's ANDA for private label version of P&U's Rogaine Extra Strength for Men was tentatively approved July 22 (1"The Rose Sheet" Aug. 2, In Brief)
You may also be interested in...
Private label minoxidil 5%
Alpharma abbreviated new drug application (75-518) for private label version of Pharmacia & Upjohn's Rogaine Extra Strength for Men tentatively approved July 22. Three-year marketing exclusivity for P&U's 5% minoxidil topical solution expires Nov. 14, 2000
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle